Ixekizumab Improves Physical Function, Quality of Life, and Work Productivity in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients with Active Psoriatic Arthritis

The document reports on a study that found ixekizumab (IXE), an anti-IL-17A monoclonal antibody, significantly improves quality of life (QoL), physical function, and work productivity in biologic disease-modifying antirheumatic drug (bDMARD)-naive patients with active psoriatic arthritis (PSA). In the phase 3 trial (SPIRIT-P1), 417 patients were randomized to receive either placebo, adalimumab, or ixekizumab for 24 weeks. Patients treated with ixekizumab reported significantly greater improvements compared to placebo in various patient-reported outcomes at weeks 12 and 24. Adalimumab also demonstrated efficacy. The study concluded that ixekizumab significantly improves QoL, physical function, and work productivity as early as week 12 and is supported by Eli Lilly and Company.